Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Biomarker/Laboratory analysis, Treatment	Active	18 and over	NCI	UCCRC-14203B NCI-7103, 7103, NCT00309946

Trial Description

Purpose:

AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable disease
• No brain metastases
• At least 4 weeks since chemotherapy, radiation therapy, or surgery
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive ADZ2171 by mouth once a day. Treatment may continue for as long as benefit is shown. Blood will be collected periodically for laboratory studies.

After finishing treatment, patients will be evaluated for up to 8 weeks.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

University of Chicago Cancer Research Center

Hedy Kindler, MD, Principal investigator		Ph: 773-702-0360; 888-824-0200

U.S.A.
California
	Beverly Hills
	Tower Cancer Research Foundation
		Philomena McAndrew, MD	Ph:  310-888-8680
	Duarte
	City of Hope Comprehensive Cancer Center
		Clinical Trials Office - City of Hope Comprehensive Cancer Center	Ph:  800-826-4673
			Email: becomingapatient@coh.org
	Los Angeles
	USC/Norris Comprehensive Cancer Center and Hospital
		Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital	Ph:  323-865-0451
	Martinez
	Contra Costa Regional Medical Center
		Sharon Hiner, MD	Ph:  925-370-5114 800-232-4636
			Email: shiner@hsd.co.contra-costa.ca.us
	Sacramento
	University of California Davis Cancer Center
		Clinical Trials Office - University of California Davis Cancer Center	Ph:  916-734-3089
	South Pasadena
	City of Hope Medical Group
		Mark McNamara, MD	Ph:  626-396-2900
			Email: mmcnamara@ccsmg.com
Illinois
	Chicago
	University of Chicago Cancer Research Center
		Clinical Trials Office - University of Chicago Cancer Research Center	Ph:  773-834-7424
	Decatur
	Decatur Memorial Hospital Cancer Care Institute
		Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute	Ph:  217-876-6601
	Evanston
	Evanston Hospital
		Clinical Trials Office - Evanston Hospital	Ph:  847-570-1381
	Harvey
	Ingalls Cancer Care Center at Ingalls Memorial Hospital
		Clinical Trials Office - Ingalls Cancer Care Center at Ingalls Memorial Hospital	Ph:  708-915-6747
	Maywood
	Cardinal Bernardin Cancer Center at Loyola University Medical Center
		Clinical Trials Office - Cardinal Bernardin Cancer Center	Ph:  708-226-4357
	Peoria
	Oncology Hematology Associates of Central Illinois, PC - Peoria
		Sachdev Thomas, MD	Ph:  309-243-1000
			Email: sthomas@ohaci.com
	Springfield
	Central Illinois Hematology Oncology Center
		Edem Agamah, MD, MS	Ph:  217-525-2500
			Email: ihdn@aol.com
Indiana
	Fort Wayne
	Fort Wayne Medical Oncology and Hematology
		David Sciortino, MD	Ph:  260-484-8830 800-852-2333
	South Bend
	CCOP - Northern Indiana CR Consortium
		David Taber, MD	Ph:  574-647-3353 800-284-7370
Michigan
	Saint Joseph
	Oncology Care Associates, PLLC
		Eric Lester, MD	Ph:  269-985-0029
Pennsylvania
	Hershey
	Penn State Cancer Institute at Milton S. Hershey Medical Center
		Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center	Ph:  717-531-3779
			Email: CTO@hmc.psu.edu
Wisconsin
	Milwaukee
	Medical College of Wisconsin Cancer Center
		Clinical Trials Office - Medical College of Wisconsin Cancer Center	Ph:  414-805-4380
Canada
Ontario
	Toronto
	Princess Margaret Hospital
		Natasha Leighl, MD, FRCPC	Ph:  416-946-2399

Registry Information
Official Title		Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma
Trial Start Date		2005-12-05
Trial Completion Date		2006-10-01 (estimated)
Registered in ClinicalTrials.gov		NCT00309946
Date Submitted to PDQ		2005-12-09
Information Last Verified		2007-06-03
NCI Grant/Contract Number		CM17102, CA14599

Back to Top